Hyperlipidemia – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, ‘Hyperlipidemia – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. Hyperlipidemia – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hyperlipidemia.
- A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hyperlipidemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Hyperlipidemia – Pipeline Review, H2 2012
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hyperlipidemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Hyperlipidemia 10
Hyperlipidemia Therapeutics under Development by Companies 12
Hyperlipidemia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Hyperlipidemia Therapeutics - Products under Development by Companies 19
Hyperlipidemia Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Hyperlipidemia Therapeutics Development 21
Samyang Corporation 21
Daewoong Pharmaceutical Co., Ltd. 22
Dr. Reddy's Laboratories Limited 23
Aegerion Pharmaceuticals, Inc. 24
Idera Pharmaceuticals, Inc. 25
Ligand Pharmaceuticals Incorporated 26
Medicure Inc. 27
Yuhan Corporation 28
WhanIn Pharmaceutical Co., Ltd. 29
Hanall Pharmaceutical Co., Ltd. 30
Ahn-Gook Pharmaceutical Co., Ltd. 31
Metabolex, Inc 32
aRigen Pharmaceuticals, Inc. 33
Esperion Therapeutics, Inc. 34
Hyperlipidemia - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
Metabasis drug for Diabetes And Hyperlipidemia - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
IMO-3100 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MBX-8025 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
IMD-5 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DRL-17822 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HL040 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HL040 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ARMAK-105 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ETC-1002 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Atorvastatin + Aspirin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Simvastatin + Aspirin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
HL-037 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HL-013 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Thyroid Receptor-beta Agonist Program - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MC-1 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
raltegravir - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HL 007 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HL 007 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
atorvastatin calcium - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HL053 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ARBs + Statins - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drug For Hyperlipidemia - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Polypill - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 67
atorvastatin calcium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
pterostilbene - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JCH2 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
HCP0912 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
HCP1007 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
WIB-901H - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AG-SAA010 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Hyperlipidemia Therapeutics - Drug Profile Updates 76
Hyperlipidemia Therapeutics - Discontinued Products 83
Hyperlipidemia Therapeutics - Dormant Products 84
Hyperlipidemia - Product Development Milestones 86
Featured News & Press Releases 86
Sep 28, 2012: Pronova And Takeda Announce New Drug Application Approval For Lotriga 2g In Japan For Treatment Of Hyperlipidemia 86
Aug 13, 2012: Ranbaxy Shifts Production Of Generic Lipitor To Mohali, India 86
Apr 27, 2012: Merck Wins US Zetia/Vytorin Patent Infringement Lawsuit 86
Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040 87
Mar 19, 2012: Pronova And Takeda Announce Results From Phase III Trial Of TAK-085 At Japanese Circulation Society 87
Jan 25, 2012: FDA Does Not Approve New Indications For ZETIA 88
Sep 29, 2011: Pronova And Takeda Announce Submission Of New Drug Application For TAK-085 In Japan For Treatment Of Hyperlipidemia 89
Jul 25, 2011: Daiichi Sankyo Receives FDA Approval For Welchol sNDA 89
Jul 18, 2011: Kowa And Lilly Report New Study Results Showing Minimal Potential For Drug Interaction Between LIVALO And Common Antiretroviral Therapy 90
Jun 23, 2011: Idera Pharmaceuticals Presents Mechanism Of Action Data Of IMO-3100 In Preclinical Model Of Arthritis At FOCIS 2011 Annual Meeting 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93
List of Tables
Number of Products Under Development for Hyperlipidemia, H2 2012 10
Products under Development for Hyperlipidemia - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Samyang Corporation, H2 2012 21
Daewoong Pharmaceutical Co., Ltd., H2 2012 22
Dr. Reddy's Laboratories Limited, H2 2012 23
Aegerion Pharmaceuticals, Inc., H2 2012 24
Idera Pharmaceuticals, Inc., H2 2012 25
Ligand Pharmaceuticals Incorporated, H2 2012 26
Medicure Inc., H2 2012 27
Yuhan Corporation, H2 2012 28
WhanIn Pharmaceutical Co., Ltd., H2 2012 29
Hanall Pharmaceutical Co., Ltd., H2 2012 30
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 31
Metabolex, Inc, H2 2012 32
aRigen Pharmaceuticals, Inc., H2 2012 33
Esperion Therapeutics, Inc., H2 2012 34
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 40
Hyperlipidemia Therapeutics - Drug Profile Updates 76
Hyperlipidemia Therapeutics - Discontinued Products 83
Hyperlipidemia Therapeutics - Dormant Products 84
List of Figures
Number of Products under Development for Hyperlipidemia, H2 2012 10
Products under Development for Hyperlipidemia - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Route of Administration, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Molecule Type, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 40
-
Importance of Optical Material in Day-to-Day Life
The most common form of optical material is in telecommunications and instruments that measure intensity, polarization and wavelength of various substances. Optical fibers are light, thin, transparent and flexible materials that act as a strong waveguide. These are a sort of glass or plastic conduits that are used for transporting light. Although invented long ago, [...]
-
Most Effective Drugs for the Treatment of Multiple Sclerosis
Also known as disseminated sclerosis, multiple sclerosis (MS) is a severe inflammatory disease. In this disease, the myelin sheath around the axon tissues of the spinal cord and brain are damaged. The loss of myelin or demyelination leads to the loss of abilities of the nerve cells. this loss is irreversible, which affects the communication [...]
-
Three Tips to Choose the Best Business Web Hosting Service
Most businesses are choosing web-based services for the convenience and additional features that they offer. Web hosting is a common internet service, which is preferred by the businesses to launch their businesses online. It is a simple process of renting a space on the server, which allows data storage. This space and data can be [...]
-
Antimalarials- Common Malaria Drugs for Fast Recovery
Malaria is one of the better-known types of the mosquito-borne infectious disease. This disease is caused by microorganisms known as protists, which are introduced into the human body thorough the bites of an infected female mosquito. Along with the common flu-like symptoms, malaria also causes several other health conditions such as gastroenteritis, septicemia and viral [...]
-
How to Choose the Best Multicasting Router
Communication is the basic of computer networking. Multicasting is a common communication process in computing, which takes place in the computing environment. Multicast is the delivery of information to a group of computers through single transmission. Digital copies of this transmission are automatically created in various other network elements. In simple terms, it is similar [...]
- Travel and Tourism in Portugal to 2017
After declining in 2009 due to the global financial crisis, the rate of inbound tourism within the Portuguese travel and tourism sector improved. The country recorded an increase in the number of international visitors and tourist expenditure, primarily due to …
- Construction in Western Europe – Key Trends and Opportunities to 2017
Western Europe experienced a severe financial crisis during 2008 – 2009, with economic activity in the region contracting sharply. Reflecting ongoing weakness in the region, real GDP has yet to rise above the pre-2008 level, with ongoing debt problems in …
- The Insurance Industry in Turkmenistan, Key Trends and Opportunities to 2017
The Turkmen insurance industry is very small, both in terms of size and significance. Insurance penetration stood at just 0.2% in 2012, compared to the global average of 6.7%. Between 2008 and 2012 the industry achieved significant written premium value …
- Construction in Thailand – Key Trends and Opportunities to 2017
The Thai construction industry suffered a double blow between 2008 and 2012, firstly from the global economic crisis in 2008 -2009 and then from the record breaking floods in 2011, with activity levels declining by 5.3% in 2008 and 2.35 …
- Construction in Tunisia – Key Trends and Opportunities to 2017
Between 2008 and 2012 the Tunisian construction industry grew at a CAGR of 5.58% and valued TND8.9 billion (US$5.7 billion) in 2012. This was supported by private and public investments in infrastructural, residential, industrial and commercial construction projects. Despite some …
Bioinformatics Market By Sector (Molecular Medicine, Agriculture, Research & Forensic), Segment (Sequencing Platforms, Knowledge Management Tools & Data Analysis Services) & Application (Genomics, Proteomics & Drug Design) – Global Forecasts to 2017
"......of data. Bioinformatics technologies are used in various pharmaceutical and biotechnology sectors. It is majorly used in the medical sector, driven by the increasing use of bioinformatics for the drug discovery and development process.
The global ......"
Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
"......ional pharmaceutical market. Utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.
The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52......"
Pharmaceutical and healthcare market in Poland 2013
"......are markets. The experienced analysts at PMR have kept close watch on these changes, observing events and collecting data that documents variations in sales values of various medications, the value of the hospital market and best-selling medicines ac......"
Brazil Pharmaceuticals and Healthcare Report Q3 2013
"......or are substantial to foreign investors due to the country's positive long-term economic outlook,
growing middle-class population and its traditional commitment to improve healthcare.
Headline Expenditure Projections
? Pharmaceuticals: BRL52.4bn (US$......"
Global Database of the Top Pharmaceutical Preparation Producers – Company Names, Financial Performance, Key Executives, and Contact Details
"......00 pharmaceutical preparation producers in the world which makes the report an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key market insights in a readily accessible and ......"
